Antiplatelet drugs in ischemic stroke prevention: From monotherapy to combined treatment

Cerebrovascular Diseases

Volumn 17, Issue SUPPL. 1, 2004, Pages 74-80

  Urbano, Luis A ^a   Bogousslavsky, Julien ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Acetylsalicylic acid; Antiplatelet agents; Clopidogrel; Dipyridamole; Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONIST; ADENYLATE CYCLASE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; NEUROPROTECTIVE AGENT; PROSTAGLANDIN SYNTHASE; PYRIDINE DERIVATIVE; THROMBOXANE; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTERY DISEASE; ARTERY INJURY; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EPIGASTRIC PAIN; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HEARTBURN; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; MONOTHERAPY; NAUSEA; NEUROPROTECTION; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 0348048844     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074800     Document Type: Conference Paper

References (37)

1. American Heart Association: Heart Disease and Stroke Statistics - 2003 Update. Dallas, American Heart Association, 2002.
2. Lusis AJ: Atherosclerosis. Nature 2000;407:233-241.
3. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
4. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
6. Sandercock PA, van den Belt AG, Lindley RI, Slattery J: Antithrombotic therapy in acute ischaemic stroke: An overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993;56:17-25.
7. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
8. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
9. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
10. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM: Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000;85:568-572.
11. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
12. Algra A, van Gijn J: Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999;66:255.
13. Sandercock P, Gubitz G, Foley P, Counsell C: Antiplatelet therapy for acute ischaemic stroke (Cochrane Review); in: The Cochrane Library. Oxford, Update Software, 2001, issue 3.
14. Roderick PJ, Wilkes HC, Meade TW: The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-226.
15. He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA 1998;280:1930-1935.
16. Reilly M, FitzGerald GA: Gathering intelligence on antiplatelet drugs: The view from 30,000 feet. When combined with other information overviews lead to conviction. BMJ 2002;324:59-60.
17. Cleland JGF: Preventing atherosclerotic events with aspirin. BMJ 2002;324:103-105.
18. Schror K: Antiplatelet drugs: A comparative review. Drugs 1995;50:7-28.
19. Hankey GJ, Sudlow CL, Dunbabin DW: Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients (Cochrane Review); in: The Cochrane Library. Oxford, Update Software, 2003, issue 3.
20. Savi P, Labouret C, Delesque N, Ghette F, Lupker J, Herbert JM: P2Y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-383.
21. Hebert JM, Frechel D, Vallee E, et al: Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993;11:180-193.
22. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
23. Harker LA, Boissel JP, Pilgrim AJ, Gent M on behalf of the CAPRIE Steering Committee and Investigators: Comparative safety and tolerability of clopidogrel and aspirin: Results from CAPRIE. Drug Saf 1999;21:325-335.
24. Fisher LD, Gent M, Büller R: Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001;141:26-32.
25. Caplan LR: Evidence based medicine: Concerns of a clinical neurologist. J Neurol Neurosurg Psychiatry 2001;71:569-576.
26. Caro JJ, Migliaccio-Walle K for the CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group: Generalizing the results of clinical trials to actual practice: The example of clopidogrel therapy for the prevention of vascular events. Am J Med 1999;107:568-572.
27. Bhatt DL, Foody JM, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol 2000;35(suppl A):326.
28. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus. J Am Coll Cardiol 2000; 35(suppl A):409.
29. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-368.
30. Hacke W, Hirsch AT, Topol EJ: The benefit of clopidogrel over aspirin is amplified in high-risk subgroups with a prior history of ischemic events. Eur Heart J 1999;20(suppl):666.
31. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
32. Bousser MG, Eschwege E, Haguenau M, Lefauconnier JM, Thibult N, Touboul D, Touboul PJ: 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983;14:5-14.
33. The American-Canadian Cooperative Study Group: Persantine/Aspirin Trial in cerebral ischemia. II. Endpoint results. Stroke 1985;16:406-415.
34. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPIRIT) Group: Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis 2000;10:147-150.
35. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
36. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht HJ, Zhao F, Chrolavicius S, Copland I, Fox KA for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE Study. Lancet 2001;358:527-533.
37. Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent TIA or Ischaemic Stroke (MATCH): Rationale and study design and interim baseline demographic data. On-going clinical trial session, 28th International Stroke Conference, 2003.